178 related articles for article (PubMed ID: 28066880)
1. Population Pharmacokinetic Analysis of Daclatasvir in Subjects with Chronic Hepatitis C Virus Infection.
Chan P; Li H; Zhu L; Bifano M; Eley T; Osawa M; Ueno T; Hughes E; Bertz R; Garimella T; AbuTarif M
Clin Pharmacokinet; 2017 Oct; 56(10):1173-1183. PubMed ID: 28066880
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of daclatasvir in Egyptian adolescents with genotype-4 HCV infection.
Al-Nahari MM; Abbassi MM; Ebeid FS; Hassany M; El-Sayed MH; Farid SF
Antivir Ther; 2020; 25(2):101-110. PubMed ID: 32367815
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetic Analysis for Daclatasvir and Asunaprevir in Japanese Subjects With Chronic Hepatitis C Virus Infection.
Osawa M; Ueno T; Ishikawa H; Imai Y; Garimella T
J Clin Pharmacol; 2018 Nov; 58(11):1468-1478. PubMed ID: 30063254
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetic Analysis of Daclatasvir, Asunaprevir, and Beclabuvir Combination in HCV-Infected Subjects.
Osawa M; Ueno T; Shiozaki T; Ishikawa H; Li H; Garimella T
Clin Pharmacol Drug Dev; 2019 Aug; 8(6):802-817. PubMed ID: 30629858
[TBL] [Abstract][Full Text] [Related]
5. Safety Exposure-Response Analysis for Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV-Infected Subjects.
Osawa M; Ueno T; Shiozaki T; Li H; Garimella T
J Clin Pharmacol; 2019 Apr; 59(4):557-565. PubMed ID: 30566237
[TBL] [Abstract][Full Text] [Related]
6. Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.
Jacobson I; Zeuzem S; Flisiak R; Knysz B; Lueth S; Zarebska-Michaluk D; Janczewska E; Ferenci P; Diago M; Zignego AL; Safadi R; Baruch Y; Abdurakhmanov D; Shafran S; Thabut D; Bruck R; Gadano A; Thompson AJ; Kopit J; McPhee F; Michener T; Hughes EA; Yin PD; Noviello S
World J Gastroenterol; 2016 Mar; 22(12):3418-31. PubMed ID: 27022224
[TBL] [Abstract][Full Text] [Related]
7. Exposure-Response Analysis for Efficacy of Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV-Infected Patients.
Ueno T; Osawa M; Shiozaki T; Green M; Garimella T
Clin Pharmacol Drug Dev; 2019 Oct; 8(7):903-913. PubMed ID: 30667592
[TBL] [Abstract][Full Text] [Related]
8. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
Sulkowski MS; Gardiner DF; Rodriguez-Torres M; Reddy KR; Hassanein T; Jacobson I; Lawitz E; Lok AS; Hinestrosa F; Thuluvath PJ; Schwartz H; Nelson DR; Everson GT; Eley T; Wind-Rotolo M; Huang SP; Gao M; Hernandez D; McPhee F; Sherman D; Hindes R; Symonds W; Pasquinelli C; Grasela DM;
N Engl J Med; 2014 Jan; 370(3):211-21. PubMed ID: 24428467
[TBL] [Abstract][Full Text] [Related]
9. Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection.
Smith MA; Regal RE; Mohammad RA
Ann Pharmacother; 2016 Jan; 50(1):39-46. PubMed ID: 26486762
[TBL] [Abstract][Full Text] [Related]
10. Daclatasvir for the treatment of chronic hepatitis C.
Degasperi E; Aghemo A; Colombo M
Expert Opin Pharmacother; 2015; 16(17):2679-88. PubMed ID: 26549010
[TBL] [Abstract][Full Text] [Related]
11. NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection.
Herbst DA; Reddy KR
Expert Opin Investig Drugs; 2013 Oct; 22(10):1337-46. PubMed ID: 23931586
[TBL] [Abstract][Full Text] [Related]
12. Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens.
Zhou N; Han Z; Hartman-Neumann S; DeGray B; Ueland J; Vellucci V; Hernandez D; McPhee F
J Antimicrob Chemother; 2016 Dec; 71(12):3495-3505. PubMed ID: 27605597
[TBL] [Abstract][Full Text] [Related]
13. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir.
McPhee F; Hernandez D; Yu F; Ueland J; Monikowski A; Carifa A; Falk P; Wang C; Fridell R; Eley T; Zhou N; Gardiner D
Hepatology; 2013 Sep; 58(3):902-11. PubMed ID: 23504694
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection.
Zhu L; Li H; Chan P; Eley T; Gandhi Y; Bifano M; Osawa M; Ueno T; Hughes E; AbuTarif M; Bertz R; Garimella T
Infect Dis Ther; 2018 Jun; 7(2):261-275. PubMed ID: 29589331
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor.
Plaza Z; Soriano V; Vispo E; del Mar Gonzalez M; Barreiro P; Seclén E; Poveda E
Antivir Ther; 2012; 17(5):921-6. PubMed ID: 22436385
[TBL] [Abstract][Full Text] [Related]
16. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.
Karino Y; Toyota J; Ikeda K; Suzuki F; Chayama K; Kawakami Y; Ishikawa H; Watanabe H; Hernandez D; Yu F; McPhee F; Kumada H
J Hepatol; 2013 Apr; 58(4):646-54. PubMed ID: 23178977
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of Daclatasvir, Sofosbuvir, and GS-331007 in a Prospective Cohort of Hepatitis C Virus-Positive Kidney Transplant Recipients.
Schrezenmeier E; Hoffmann F; Jaeger C; Schrezenmeier J; Lisec J; Glander P; Algharably E; Kreutz R; Budde K; Duerr M; Halleck F
Ther Drug Monit; 2019 Feb; 41(1):53-58. PubMed ID: 30422962
[TBL] [Abstract][Full Text] [Related]
18. Association of Sofosbuvir and Daclatasvir Plasma Trough Concentrations with Patient-, Treatment-, and Disease-Related Factors Among HIV/HCV-Coinfected Persons.
Mastrorosa I; Tempestilli M; Notari S; Lorenzini P; Fabbri G; Grilli E; Bellagamba R; Vergori A; Cicalini S; Ammassari A; Agrati C; Antinori A
Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):135-142. PubMed ID: 34623616
[TBL] [Abstract][Full Text] [Related]
19. NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection.
Zhou N; Hernandez D; Ueland J; Yang X; Yu F; Sims K; Yin PD; McPhee F
J Infect Dis; 2016 Jan; 213(2):206-15. PubMed ID: 26170396
[TBL] [Abstract][Full Text] [Related]
20. Daclatasvir for the treatment of chronic hepatitis C virus infection.
Temesgen Z; Rizza SA
Drugs Today (Barc); 2015 May; 51(5):277-88. PubMed ID: 26097901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
